DR info

臨床試験数 : 38 / 薬物数 : 38 - (DrugBank : 15) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 118

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

68Ga-NEB
   Peking Union Medical College Hospital
      2019   Phase 1   NCT04273334   China;
Afinitor
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy;
   Novartis Pharma Services AG
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Afinitor 5mg Tablets
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Albuterol inhaler
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States;
Albuterol nebulizer
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States;
Bevacizumab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Celecoxib
   Brigham and Women's Hospital
      2016   Phase 2   NCT02484664   United States;
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Doxycycline
   University of Nottingham
      2009   Phase 4   NCT00989742   United Kingdom;
Doxycycline 100 mg Capsules
   University of Nottingham
      2008   -   EUCTR2007-003745-32-GB   United Kingdom;
Everolimus
   NOVARTIS FARMA
      2010   -   EUCTR2010-019825-32-IT   France;Italy;
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy;
   Novartis Pharma Services AG
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
   Novartis Pharmaceuticals
      2010   Phase 2   NCT01059318   France;Germany;Italy;United States;
   University of Cincinnati
      2015   -   NCT02432560   United States;
Everolimus (RAD001)
   Children's Hospital Medical Center, Cincinnati
      2008   Phase 1/Phase 2   NCT00792766   United States;
   Novartis Pharmaceuticals
      2009   Phase 3   NCT00790400   Canada;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Everolimus Oral Product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
Glutamine
   Vanderbilt University Medical Center
      2019   Phase 1   NCT04388371   United States;
Imatinib Mesylate 400Mg Capsule
   Medical University of South Carolina
      2018   Phase 1/Phase 2   NCT03131999   United States;
Letrozole
   University of Cincinnati
      2011   Phase 2   NCT01353209   United States;
Nintedanib
   IRCCS Multimedica
      2016   Phase 2   NCT03062943   Italy;
Octreotide
   National Heart, Lung, and Blood Institute (NHLBI)
      2000   Phase 2   NCT00005906   United States;
Ofev
   MULTIMEDICA S.P.A.
      2016   Phase 3   EUCTR2015-004919-20-IT   Italy;
PFT
   National Heart, Lung, and Blood Institute (NHLBI)
      2013   Phase 1/Phase 2   NCT01799538   United States;
RAD001
   Children's Hospital Medical Center, Cincinnati
      2005   Phase 1/Phase 2   NCT00457964   United States;
   NOVARTIS FARMA
      2009   -   EUCTR2008-002113-48-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Novartis Pharma Service AG
      2010   -   EUCTR2010-019825-32-FR   France;Italy;
   Novartis Pharma Services AG
      2010   -   EUCTR2008-002113-48-NL   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-002113-48-GB   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-002113-48-FR   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      -   Phase 3   EUCTR2008-002113-48-DE   Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
Rapamycin, sirolimus
   Children's Hospital Medical Center, Cincinnati
      2002   Phase 2   NCT00457808   United States;
Resveratrol
   University of Cincinnati
      2018   Phase 2   NCT03253913   United States;
Saracatinib
   Baylor College of Medicine
      2016   Phase 2   NCT02737202   United States;
   Tony Eissa
      2014   Phase 1   NCT02116712   United States;
Simvastatin
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
Sirolimus
   Cardiff University
      2005   Phase 2   NCT00490789   United Kingdom;
   Frank McCormack, M.D., University of Cincinnati Medical Center Director, Division of Pulmonary and Critical Care Medicine
      2008   Phase 3   JPRN-JMA-IIA00011   Japan, United States, Canada;
   Kobe University Graduate School of Medicine
      2012   -   JPRN-UMIN000007387   Japan;
   Koh Nakata, MD, Ph.D
      2011   Phase 2   JPRN-JMA-IIA00037   Japan;
   National Hospital Organization Kinki-chuo Chest Medical Center
      2015   -   JPRN-UMIN000016677   Japan;
   Office of Rare Diseases (ORD)
      2006   Phase 3   NCT00414648   Canada;Japan;United States;
   University of Cincinnati
      2018   Phase 3   NCT03150914   United States;
      2018   Phase 2   NCT03253913   United States;
      2015   -   NCT02432560   United States;
Sirolimus Oral Product
   University of Pennsylvania
      2014   Phase 1/Phase 2   NCT02061397   United States;
Sirolimus and Hydroxychloroquine
   Brigham and Women's Hospital
      2012   Phase 1   NCT01687179   United States;
Srolimus
   Koh Nakata, MD, PhD
      2012   Phase 2   JPRN-JMA-IIA00096   Japan;
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;